BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS

被引：0
|
作者：
Westerink, L. [1 ]
Nicolai, J. [2 ]
Samuelsen, C. H. [3 ]
Griebsch, I [3 ]
Postma, M. [1 ]
机构：
[1] Univ Groningen, Groningen, GR, Netherlands
[2] Boehringer Ingelheim Int GmbH, Alkmaar, Netherlands
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN187
引用
收藏
页码：S472 / S472
页数：1
相关论文
共 50 条
  • [1] Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
    Westerink, Lotte
    Nicolai, Jelmer L. J.
    Samuelsen, Carl
    Smit, Hans J. M.
    Postmus, Pieter E.
    Griebsch, Ingolf
    Postma, Maarten J.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (06): : 931 - 943
  • [2] Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
    Lotte Westerink
    Jelmer L. J. Nicolai
    Carl Samuelsen
    Hans J. M. Smit
    Pieter E. Postmus
    Ingolf Griebsch
    Maarten J. Postma
    [J]. The European Journal of Health Economics, 2020, 21 : 931 - 943
  • [3] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
    Liam, Chong-Kin
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66
  • [4] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [5] BUDGET IMPACT OF AFATINIB VS OSIMERTINIB IN FIRST-LINE TREATMENT OF EGFR COMMON MUTATION POSITIVE NSCLC IN CHINA
    Yan, J. Z.
    Gong, X. L.
    Zhao, J.
    Shao, R.
    Zhang, Y. J.
    Hong, G.
    Xue, N.
    Mu, S.
    [J]. VALUE IN HEALTH, 2020, 23 : S49 - S49
  • [6] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [7] Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Wang, Lara
    Golembesky, Amanda
    Maerten, Angela
    Cufer, Tanja
    [J]. FUTURE ONCOLOGY, 2018, 14 (27) : 2861 - 2874
  • [8] Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations
    Pompilio, Giuseppe
    Morabito, Alessandro
    Cortinovis, Diego L.
    Integlia, Davide
    [J]. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2022, 9 : 22 - 29
  • [9] First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea
    Kim, Mi-Hyun
    Choi, Chang Min
    Lee, Sung Yong
    Park, Cheol Kyu
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Chan Kwon
    Lee, Sang Hoon
    Jang, Seung Hun
    Yoon, Seong Hoon
    Jang, Tae Won
    [J]. ANTICANCER RESEARCH, 2022, 42 (03) : 1615 - 1622
  • [10] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
12345